Michael R. Verneris

This study identifies metabolic vulnerabilities in Down syndrome B-cell acute lymphoblastic leukemia and shows that Venetoclax effectively targets these vulnerabilities.

This study compares the tonsillar microbiome of children with Down syndrome and obstructive sleep apnea to non-DS OSA patients, finding specific microbial shifts in DS tonsils.

This study identifies hyperactive interferon signaling and lymphoid tissue disorganization as drivers of adaptive immune dysfunction in Down syndrome across development and aging.